The theme of this research is drug delivery with an emphasis on products of the pharmaceutical biotechnology industry including peptide/protein type drugs, plasmid DNA and siRNA. Biopharmaceuticals, including peptide/proteins and nucleic acids, which are now approaching 50% of all new drugs in development.
It is well accepted that the major barrier to translating these product into the clinic is the design of efficient, non-toxic delivery systems. Thus the focus of Prof O’Driscoll’s research is the development of nano-sized delivery constructs which are robust enough to survive processing, are stable on storage and achieve cell /site specific delivery in vivo.
Such targeted systems aim to increase therapeutic efficacy and reduce side effects thus ensuring improved patient outcomes.